Literature DB >> 21543849

Pi sampling: a methodical and flexible approach to initial macromolecular crystallization screening.

Fabrice Gorrec1, Colin M Palmer, Guillaume Lebon, Tony Warne.   

Abstract

The Pi sampling method is derived from the incomplete factorial approach to macromolecular crystallization screen design. The resulting `Pi screens' have a modular distribution of a given set of up to 36 stock solutions. Maximally diverse conditions can be produced by taking into account the properties of the chemicals used in the formulation and the concentrations of the corresponding solutions. The Pi sampling method has been implemented in a web-based application that generates screen formulations and recipes. It is particularly adapted to screens consisting of 96 different conditions. The flexibility and efficiency of Pi sampling is demonstrated by the crystallization of soluble proteins and of an integral membrane-protein sample.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21543849      PMCID: PMC3087625          DOI: 10.1107/S0907444911008754

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


Introduction

A crucial aspect of macromolecular crystallographic studies is finding suitable conditions for the crystallization of a sample. This can be difficult because many factors alter the crystallization behaviour of macromolecules, including the type and the concentration of the chemicals employed to formulate the conditions (McPherson, 1990 ▶). A condition includes at least a precipitant and most conditions also include a buffer and an additive. During the initial crystallization experiments, the structure of the macromolecule is not known and hence the most efficient formulation cannot be predicted. As a consequence, one should be cautious when making initial assumptions and limiting choices in subsequent optimizations (Rupp, 2003 ▶). Nonetheless, the number of initial crystallization con­ditions cannot be unreasonably large since purified protein is often difficult and expensive to produce in large quantities. There are essentially two approaches to restrict an initial screen to a limited number of crystallization conditions. Firstly, a sparse-matrix formulation can be used, which consists of an empirically derived combination of components based on known or published crystallization conditions (Jancarik & Kim, 1991 ▶). Secondly, an incomplete factorial formulation can be generated in which selected components are combined to prepare new conditions in accordance with principles of randomization and balance (Carter & Carter, 1979 ▶). Numerous commercial screens based on these two main approaches are available. Automated systems have been implemented at the Medical Research Council (MRC) Laboratory of Molecular Biology (LMB) to test these as routine initial screens using the 96-well crystallization plate format (Stock et al., 2005 ▶). However, for various reasons, many laboratories opt for a minimal screen (Kimber et al., 2003 ▶) and still perform at least some aspects of the work manually (Bergfors, 2007 ▶). Here, we present a development based on the incomplete factorial formulation: the Pi sampling method. The name of the method was inspired by the story of Archimedes, who used the ‘method of exhaustion’ (i.e. an empirical approach) with a 96-sided polygon in order to reach the first good numerical approximation of π (Smith, 1958 ▶). Pi sampling uses modular arithmetic to form combinations of three stock solutions across a 96-condition grid. Maximally diverse conditions can be produced by taking into account the properties of the chemicals used in the formulation and the concentrations of the corresponding stock solutions. We have implemented this approach in a web-based application called Pi Sampler: user input consists of the details of up to 36 stock solutions, from which the application generates the formulations for a 96-­condition screen. The Pi sampling method is intended to help laboratories to test new crystallization-screen formulations on a day-to-day basis based on the properties of the macromolecules investigated, as has been performed pre­viously with RNA (Doudna et al., 1993 ▶). Firstly, we tested Pi sampling with ten commercially available soluble proteins. For this, the ‘Pi minimal screen’ was employed including a wide variety of well known chemicals frequently used for macromolecular crystallization. We then investigated the impact of Pi sampling on the crystallization of a G-protein-coupled receptor (GPCR) that had been difficult to crystallize: the adenosine A2A receptor (construct A2AR-GL31). We formulated another Pi screen, the ‘Pi-PEG screen’, taking into consideration general observations made about crystallization of integral membrane-protein samples. Previous crystallization experiments on another GPCR (the β1-adrenergic receptor) had indicated that the use of simple proprietary screens formulated with poly(ethylene glycol) (PEG) and buffers gave a greater yield of crystals than all commercially available screens, including those geared towards membrane proteins (Warne et al., 2009 ▶), and the 2.7 Å resolution structure was solved using conditions optimized from a proprietary screen essentially based on PEGs (Warne et al., 2008 ▶). This has been observed previously with other membrane-protein targets (Lemieux et al., 2003 ▶). In addition, mixtures of polyethylene glycols have been used successfully to develop a minimal screen (Brzozowski & Walton, 2001 ▶) and to study crystal structures of the Kir potassium channel (Clarke et al., 2010 ▶). Such mixtures were incorporated into the Pi-PEG screen.

Methods

Pi sampling

Pi sampling begins with up to 36 stock solutions, divided into three sets of 12. The first set of solutions is used in the screen at constant concentration. The second and third sets are added according to a gradient between specified minimum and maximum concentrations. Typically, the first set is com­posed of buffers and the second and third sets are precipitants/additives. The combinations of three stock solutions (one from each set) are generated according to Fig. 1 ▶, where 1–12 refer to the IDs for solutions of the first set, A–M to those of the second set and N–X to those of the third set. The number in each cell shows which solution of the first set will be combined with the corresponding solutions of the second and third sets. Blank spaces show when no such combinations are generated.
Figure 1

Pi sampling: combinations of stock solutions from three different sets (see also http://pisampler.mrc-lmb.cam.ac.uk/).

Fig. 2 ▶ summarizes the distribution of the stock solutions in a standard 96-condition plate layout (i.e. 12 columns and eight rows).
Figure 2

Pi sampling: combinations of the stock solutions in a 96-condition plate layout (well A1 is at the top left corner). Each solution of set 1 (ID 1–12) is seen in the eight conditions forming a column of the plate. The Δ values of set 1 increase from left to right in the screen layout. The positions of the solutions A–L (set 2) shift across five columns and down one row (Δ values not represented). The positions of solutions M–X (set 3) shift across ten columns and down one row. Gradients of concentration for sets 2 and 3 are represented on the left and right, respectively.

Set 1: each solution (ID 1–12) is seen in the eight conditions forming a column of the plate. A variable Δ should be associated with the stock solutions. The variable Δ corresponds to a property of the solution selected (e.g. pH, molecular weight of the main chemical, absorption properties or others). Δ values increase from left to right in the screen layout. Set 2: each solution (ID A–L) is represented once in each row. The final concentrations decrease gradually from the top to the bottom of the screen layout, forming a gradient. The distribution of solutions A–L is based on the sequence of Δ values established for set 1: the positions of the solutions shift across five columns and down one row. Solutions A–L should also be associated with a variable Δ and hence a sequence is formed for the distribution of the third set of solutions. Set 3: each solution (ID M–X) is also represented once in each row. The final concentrations increase gradually from the top to the bottom of the screen, forming another gradient. The solutions M–X are distributed with the same modulo arithmetic operation as previously, but with respect to the Δ values of solutions A–L. For example, solution M is mixed with solution A in the first row, solution F in the second row, solution K in the third row and so on, as shown in Fig. 2 ▶. This means that both the second and third sets are arranged according to the same modulo arithmetic operation (5 modulo 12); however, when looking at the plate layout, the positions of solutions M–X shift across ten columns and down one row.

Pi Sampler

Pi Sampler can be accessed via the internet at http://pisampler.mrc-lmb.cam.ac.uk/. Users can enter the details of up to 36 stock solutions, including stock concentrations, desired screen concentration ranges and Δ values. The application then generates a 96-condition screen formulation following the Pi sampling method described above. Formulations, recipes and total required volumes of stock solutions are presented and may conveniently be downloaded in comma-separated variable format (CSV), allowing the user to import them into other software for automated screen making (Cox & Weber, 1987 ▶), formulation analysis (Hedderich et al., 2011 ▶) and data mining (Kantardjieff & Rupp, 2004 ▶). The parameters used to generate the screen can also be saved and uploaded in the same format. Further details and instructions can be found on the website.

Pi minimal screen preparation and crystallization assays with commercially available soluble proteins

The final formulation of the Pi minimal screen can be found in Table 1 ▶. There are 36 starting stock solutions overall. Each solution composing the first set (ID 1–12) is a mixture of an acid with its corresponding base (e.g. HEPES pH 7.5: 1 M HEPES solution mixed with 1 M HEPES sodium salt in order to reach pH 7.5), except for buffer 11 (AMPD mixed with Tris base). Note that this is also true for the precipitant phosphate (phosphate system: sodium dihydrogen phosphate/dipotassium hydrogen phosphate). Values of pH (4.0–9.5) were chosen as the variable Δ for the first set, whilst arbitrary values were chosen for additives of various natures composing the second set (ID A–L). Eventually, a few conditions were made without additive/buffer because of chemical incompatibilities (Table 1 ▶).
Table 1

Final formulation of the Pi minimal screen

ADA, N-(2-acetamido)iminodiacetic acid; AMPD, 2-amino-2-methyl-1,3-propanediol; CAPSO, 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid; HEPES, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid; MOPS, 3-(N-morpholino)propanesulfonic acid; PEG, poly(ethylene glycol); TAPS, N-[Tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid.

 Set 1Set 2Set 3
WellIDNameConc.UnitIDNameConc.UnitIDNameConc.Unit
A11Formate pH 4.00.15 M APotassium bromide0.160 M MPhosphate0.6 M
A22Acetate pH 4.50.15 M BPEG 3008.000%(v/v)NPEG MME 55024.00%(v/v)
A33Malate pH 5.00.15 M CMagnesium sulfate0.160 M OAmmonium nitrate2.0 M
A44Citrate pH 5.50.15 M DSodium fluoride0.032 M PPEG 2000010.0%(w/v)
A55MES pH 6.00.15 M EPotassium thiocyanate0.080 M QPEG 100030.0%(w/v)
A66Cacodylate pH 6.50.15 M FSodium iodide0.160 M RSodium chloride1.6 M
A77MOPS pH 7.00.15 M GPropanediol8.000%(v/v)SPEG 400024.0%(w/v)
A88HEPES pH 7.50.15 M H   TLithium sulfate0.8 M
A99Tris pH 8.00.15 M IEthylene glycol8.000%(v/v)UPEG MME 500020.0%(w/v)
A1010TAPS pH 8.50.15 M JSodium potassium tartrate0.080 M VGlycerol36.0%(w/v)
A1111AMPD/Tris pH 9.00.15 M KMPD8.000%(v/v)WAmmonium sulfate1.4 M
A1212CAPSO pH 9.50.15 M L2-Butanol8.000%(v/v)XPEG 800020.0%(w/v)
B11Formate pH 4.00.15 M HCalcium chloride0.070 M OAmmonium nitrate2.3 M
B22Acetate pH 4.50.15 M IEthylene glycol7.000%(v/v)PPEG 2000012.0%(w/v)
B33Malate pH 5.00.15 M JSodium potassium tartrate0.070 M QPEG 100035.0%(w/v)
B44Citrate pH 5.50.15 M KMPD7.000%(v/v)RSodium chloride1.8 M
B55MES pH 6.00.15 M L2-Butanol7.000%(v/v)SPEG 400028.0%(w/v)
B66Cacodylate pH 6.50.15 M APotassium bromide0.140 M TLithium sulfate0.9 M
B77MOPS pH 7.00.15 M BPEG 3007.000%(v/v)UPEG MME 500023.0%(w/v)
B88HEPES pH 7.50.15 M CMagnesium sulfate0.140 M VGlycerol42.0%(w/v)
B99Tris pH 8.00.15 M DSodium fluoride0.028 M WAmmonium sulfate1.6 M
B1010TAPS pH 8.50.15 M EPotassium thiocyanate0.070 M XPEG 800023.0%(w/v)
B1111AMPD/Tris pH 9.00.15 M FSodium iodide0.140 M MPhosphate0.7 M
B1212CAPSO pH 9.50.15 M GPropanediol7.000%(v/v)NPEG MME 55028.00%(v/v)
C11Formate pH 4.00.15 M CMagnesium sulfate0.120 M QPEG 100039.0%(w/v)
C22Acetate pH 4.50.15 M DSodium fluoride0.024 M RSodium chloride2.1 M
C33Malate pH 5.00.15 M EPotassium thiocyanate0.060 M SPEG 400031.0%(w/v)
C44Citrate pH 5.50.15 M FSodium iodide0.120 M TLithium sulfate1.0 M
C55MES pH 6.00.15 M GPropanediol6.000%(v/v)UPEG MME 500026.0%(w/v)
C66Cacodylate pH 6.50.15 M HCalcium chloride0.060 M VGlycerol47.0%(w/v)
C77MOPS pH 7.00.15 M IEthylene glycol6.000%(v/v)WAmmonium sulfate1.8 M
C88HEPES pH 7.50.15 M JSodium potassium tartrate0.060 M XPEG 800026.0%(w/v)
C99Tris pH 8.00.15 M KMPD6.000%(v/v)MPhosphate0.8 M
C1010TAPS pH 8.50.15 M L2-Butanol6.000%(v/v)NPEG MME 55031.00%(v/v)
C1111AMPD/Tris pH 9.00.15 M APotassium bromide0.120 M OAmmonium nitrate2.6 M
C1212CAPSO pH 9.50.15 M BPEG 3006.000%(v/v)PPEG 2000013.0%(w/v)
D11Formate pH 4.00.15 M J   SPEG 400035.0%(w/v)
D22Acetate pH 4.50.15 M KMPD5.000%(v/v)TLithium sulfate1.1 M
D33Malate pH 5.00.15 M L2-Butanol5.000%(v/v)UPEG MME 500038.00%(v/v)
D44Citrate pH 5.50.15 M APotassium bromide0.100 M VGlycerol52.0%(w/v)
D55MES pH 6.00.15 M BPEG 3005.000%(v/v)WAmmonium sulfate2.0 M
D66Cacodylate pH 6.50.15 M CMagnesium sulfate0.100 M XPEG 800029.0%(w/v)
D77MOPS pH 7.00.15 M DSodium fluoride0.020 M MPhosphate0.9 M
D88HEPES pH 7.50.15 M EPotassium thiocyanate0.050 M NPEG MME 55034.00%(v/v)
D99Tris pH 8.00.15 M FSodium iodide0.100 M OAmmonium nitrate2.9 M
D1010TAPS pH 8.50.15 M GPropanediol5.000%(v/v)PPEG 2000015.0%(w/v)
D1111   HCalcium chloride0.050 M QPEG 100043.0%(w/v)
D1212CAPSO pH 9.50.15 M IEthylene glycol5.000%(v/v)RSodium chloride2.3 M
E11Formate pH 4.00.15 M EPotassium thiocyanate0.040 M UPEG MME 500032.0%(w/v)
E22Acetate pH 4.50.15 M FSodium iodide0.080 M VGlycerol57.0%(w/v)
E33Malate pH 5.00.15 M GPropanediol4.000%(v/v)WAmmonium sulfate2.2 M
E44Citrate pH 5.50.15 M H   XPEG 800032.0%(w/v)
E55MES pH 6.00.15 M IEthylene glycol4.000%(v/v)MPhosphate0.9 M
E66Cacodylate pH 6.50.15 M JSodium potassium tartrate0.040 M NPEG MME 55038.0%(v/v)
E77MOPS pH 7.00.15 M KMPD4.000%(v/v)OAmmonium nitrate3.1 M
E88HEPES pH 7.50.15 M L2-Butanol4.000%(v/v)PPEG 2000016.0%(w/v)
E99Tris pH 8.00.15 M APotassium bromide0.080 M QPEG 100048.0%(w/v)
E1010TAPS pH 8.50.15 M BPEG 3004.000%(v/v)RSodium chloride2.5 M
E1111AMPD/Tris pH 9.00.15 M CMagnesium sulfate0.080 M SPEG 400038.0%(w/v)
E1212CAPSO pH 9.50.15 M D   TLithium sulfate1.3 M
F11Formate pH 4.00.15 M L2-Butanol3.000%(v/v)WAmmonium sulfate2.4 M
F22Acetate pH 4.50.15 M APotassium bromide0.060 M XPEG 800035.0%(w/v)
F33Malate pH 5.00.15 M BPEG 3003.000%(v/v)MPhosphate1.0 M
F44   CMagnesium sulfate0.06 M NPEG MME 55042.00%(v/v)
F55MES pH 6.00.15 M DSodium fluoride0.012 M OAmmonium nitrate3.4 M
F66Cacodylate pH 6.50.15 M EPotassium thiocyanate0.030 M PPEG 2000018.0%(w/v)
F77MOPS pH 7.00.15 M FSodium iodide0.060 M QPEG 100052.0%(w/v)
F88HEPES pH 7.50.15 M GPropanediol3.000%(v/v)RSodium chloride2.7 M
F99Tris pH 8.00.15 M HCalcium chloride0.030 M SPEG 400042.0%(w/v)
F1010TAPS pH 8.50.15 M IEthylene glycol3.000%(v/v)TLithium sulfate1.4 M
F1111AMPD/Tris pH 9.00.15 M JSodium potassium tartrate0.030 M UPEG MME 500035.0%(w/v)
F1212CAPSO pH 9.50.15 M KMPD3.000%(v/v)VGlycerol62.0%(w/v)
G11Formate pH 4.00.15 M GPropanediol2.000%(v/v)MPhosphate1.1 M
G22Acetate pH 4.50.15 M H   NPEG MME 55045.00%(v/v)
G33Malate pH 5.00.15 M IEthylene glycol2.000%(v/v)OAmmonium nitrate3.7 M
G44Citrate pH 5.50.15 M JSodium potassium tartrate0.020 M PPEG 2000019.0%(w/v)
G55MES pH 6.00.15 M KMPD2.000%(v/v)QPEG 100056.0%(w/v)
G66Cacodylate pH 6.50.15 M L2-Butanol2.000%(v/v)RSodium chloride3.0 M
G77MOPS pH 7.00.15 M APotassium bromide0.040 M SPEG 400045.0%(w/v)
G88HEPES pH 7.50.15 M BPEG 3002.000%(v/v)TLithium sulfate1.5 M
G99Tris pH 8.00.15 M CMagnesium sulfate0.040 M UPEG MME 500038.0%(w/v)
G1010TAPS pH 8.50.15 M DSodium fluoride0.008 M VGlycerol67.0%(w/v)
G1111AMPD/Tris pH 9.00.15 M EPotassium thiocyanate0.020 M WAmmonium sulfate2.6 M
G1212CAPSO pH 9.50.15 M FSodium iodide0.040 M XPEG 800038.0%(w/v)
H11Formate pH 4.00.15 M BPEG 3001.000%(v/v)OAmmonium nitrate4.0 M
H22Acetate pH 4.50.15 M CMagnesium sulfate0.020 M PPEG 2000020.0%(w/v)
H33Malate pH 5.00.15 M DSodium fluoride0.004 M QPEG 100060.0%(w/v)
H44Citrate pH 5.50.15 M EPotassium thiocyanate0.010 M RSodium chloride3.2 M
H55MES pH 6.00.15 M FSodium iodide0.020 M SPEG 400048.0%(w/v)
H66Cacodylate pH 6.50.15 M GPropanediol1.000%(v/v)TLithium sulfate1.6 M
H77MOPS pH 7.00.15 M HCalcium chloride0.010 M UPEG MME 500040.0%(w/v)
H88HEPES pH 7.50.15 M IEthylene glycol1.000%(v/v)VGlycerol72.0%(w/v)
H99Tris pH 8.00.15 M JSodium potassium tartrate0.010 M WAmmonium sulfate2.8 M
H1010TAPS pH 8.50.15 M KMPD1.000%(v/v)XPEG 800040.0%(w/v)
H1111AMPD/Tris pH 9.00.15 M L2-Butanol1.000%(v/v)MPhosphate1.2 M
H1212CAPSO pH 9.50.15 M APotassium bromide0.020 M NPEG MME 55048.00%(v/v)
Highest purity grade chemicals (Molecular Biology grade when available) were purchased from Sigma–Aldrich to prepare 36 stock solutions. The solutions were mixed in 96 Falcon tubes. The screen was dispensed into ‘MRC original plates’ (96-well, two-drop, Swissci; Stock et al., 2005 ▶). Commercial proteins that had been crystallized before were chosen to prepare test samples. Protein concentrations were chosen randomly between 7 and 150 mg ml−1 (Table 2 ▶). Vapour-diffusion experiments were set up at 295 K, mixing two different sample: condition ratios (1:3 and 3:1) to give a final volume of 400 nl. The plates were then stored at 291 K. A condition was considered to be a hit when at least one of the two corresponding drops con­tained crystals with well known morphology after one week. Table 3 ▶ shows the ‘hits per con­dition’ observed and the corresponding results expected for the binomial distribution (see §4.2).
Table 2

Details of the samples used with the Pi minimal screen (Table 1 ▶) and number of crystallization hits

TEN, buffer consisting of 20mM 2-amino-2-(hydroxymethyl)-1,3-propanediol (Tris), 1mM ethylenediaminetetraacetic acid (EDTA), 1mM sodium azide and 200mM sodium chloride.

ProteinConcentration (mgml1)MW (kDa)Source and codeBuffer/preparationHits
Lysozyme10.014.4Sigma L6876Deionized water56
Concanavalin A7.026.5Sigma L7647TEN pH 8.516
Glucose isomerase33.043.0Hampton HR7-102See product user guide11
Xylanase36.021.0Hampton HR7-106See product user guide8
Ferritin50150440.0Fluka 96701As supplied by the manufacturer8
Catalase12.662.5Sigma C3155Deionized water6
Citrate synthase10.049.0Sigma C3260TEN pH 8.55
Lipase B25.035.0Hampton HR7-099Deionized water4
Ribonuclease A30.013.7Sigma R5503Deionized water1
Thaumatin30.022.0Sigma T7638Deionized water1
Sum    116
Table 3

‘Hits per condition’ observed and corresponding results expected with the binomial distribution (Pi minimal screen)

Hits/conditionObservedExpected
02126.5
14536.4
22022.5
3 or more1010.6
Sum9696

Pi-PEG screen preparation and crystallization assays with a GPCR

The final formulation of the Pi-PEG screen can be found in Table 4 ▶. The formulation can also be generated using Pi Sampler by loading the Pi-PEG example data. The pH values (4.8–8.8) were chosen as the variable Δ for the buffers composing set 1 (ID 1–12), whilst molecular weight was chosen for set 2 (PEGs A–L, final concentration range 0–22.5%). The same 12 PEGs were used for set 3 (PEGs M–X, final concentration range 0–45%). General details of the preparation are similar to §2.3, but there are 24 stock solutions at the start (instead of 36). Vapour-diffusion experiments were set up at 277 K, mixing sample and condition in a 1:1 ratio to give a final volume of 200 nl. The preparation of A2AR-GL31 will be published elsewhere (Lebon et al., submitted work). Crystal X-ray screening was performed at the Diamond synchrotron light source (microfocus beamline I24 equipped with a Pilatus 6M detector).
Table 4

Final formulation of the Pi-PEG screen

 Set 1Set 2Set 3
WellIDNameConc.UnitIDNameConc.UnitIDNameConc.Unit
A11Acetate pH 4.80.05 M APEG 20022.5%(v/v)M   
A22Acetate pH 5.20.05 M BPEG 30020.0%(v/v)N   
A33MES pH 5.60.05 M CPEG MME 35020.0%(v/v)O   
A44MES pH 6.00.05 M DPEG 40020.0%(v/v)P   
A55ADA pH 6.40.05 M EPEG MME 55020.0%(v/v)Q   
A66ADA pH 6.80.05 M FPEG 60020.0%(v/v)R   
A77HEPES pH 7.10.05 M GPEG 100017.5%(w/v)S   
A88HEPES pH 7.30.05 M HPEG 150017.5%(w/v)T   
A99Tris pH 7.60.05 M IPEG 200015.0%(w/v)U   
A1010Tris pH 8.00.05 M JPEG MME 200015.0%(w/v)V   
A1111Bicine pH 8.40.05 M KPEG 300015.0%(w/v)W   
A1212Bicine pH 8.80.05 M LPEG 400015.0%(w/v)X   
B11Acetate pH 4.80.05 M HPEG 150015.0%(w/v)OPEG 40003.6%(w/v)
B22Acetate pH 5.20.05 M IPEG 200012.9%(w/v)PPEG 2006.4%(v/v)
B33MES pH 5.60.05 M JPEG MME 200012.9%(w/v)QPEG 3005.7%(v/v)
B44MES pH 6.00.05 M KPEG 300012.9%(w/v)RPEG MME 3505.7%(v/v)
B55ADA pH 6.40.05 M LPEG 400012.9%(w/v)SPEG 4005.7%(v/v)
B66ADA pH 6.80.05 M APEG 20019.3%(v/v)TPEG MME 5505.7%(v/v)
B77HEPES pH 7.10.05 M BPEG 30017.1%(v/v)UPEG 6005.7%(v/v)
B88HEPES pH 7.30.05 M CPEG MME 35017.1%(v/v)VPEG 10005.0%(w/v)
B99Tris pH 7.60.05 M DPEG 40017.1%(v/v)WPEG 15005.0%(w/v)
B1010Tris pH 8.00.05 M EPEG MME 55017.1%(v/v)XPEG 20004.3%(w/v)
B1111Bicine pH 8.40.05 M FPEG 60017.1%(v/v)MPEG MME 20004.3%(w/v)
B1212Bicine pH 8.80.05 M GPEG 100015.0%(w/v)NPEG 30004.3%(w/v)
C11Acetate pH 4.80.05 M CPEG MME 35014.3%(v/v)QPEG 30011.4%(v/v)
C22Acetate pH 5.20.05 M DPEG 40014.3%(v/v)RPEG MME 35011.4%(v/v)
C33MES pH 5.60.05 M EPEG MME 55014.3%(v/v)SPEG 40011.4%(v/v)
C44MES pH 6.00.05 M FPEG 60014.3%(v/v)TPEG MME 55011.4%(v/v)
C55ADA pH 6.40.05 M GPEG 100012.5%(w/v)UPEG 60011.4%(v/v)
C66ADA pH 6.80.05 M HPEG 150012.5%(w/v)VPEG 100010.0%(w/v)
C77HEPES pH 7.10.05 M IPEG 200010.7%(w/v)WPEG 150010.0%(w/v)
C88HEPES pH 7.30.05 M JPEG MME 200010.7%(w/v)XPEG 20008.6%(w/v)
C99Tris pH 7.60.05 M KPEG 300010.7%(w/v)MPEG MME 20008.6%(w/v)
C1010Tris pH 8.00.05 M LPEG 400010.7%(w/v)NPEG 30008.6%(w/v)
C1111Bicine pH 8.40.05 M APEG 20016.1%(v/v)OPEG 40007.1%(w/v)
C1212Bicine pH 8.80.05 M BPEG 30014.3%(v/v)PPEG 20012.9%(v/v)
D11Acetate pH 4.80.05 M JPEG MME 20008.6%(w/v)SPEG 40017.1%(w/v)
D22Acetate pH 5.20.05 M KPEG 30008.6%(w/v)TPEG MME 55017.1%(v/v)
D33MES pH 5.60.05 M LPEG 40008.6%(w/v)UPEG 60017.1%(v/v)
D44MES pH 6.00.05 M APEG 20012.9%(v/v)VPEG 100015.0%(w/v)
D55ADA pH 6.40.05 M BPEG 30011.4%(v/v)WPEG 150015.0%(w/v)
D66ADA pH 6.80.05 M CPEG MME 35011.4%(v/v)XPEG 200012.9%(w/v)
D77HEPES pH 7.10.05 M DPEG 40011.4%(v/v)MPEG MME 200012.9%(w/v)
D88HEPES pH 7.30.05 M EPEG MME 55011.4%(v/v)NPEG 300012.9%(w/v)
D99Tris pH 7.60.05 M FPEG 60011.4%(v/v)OPEG 400010.7%(w/v)
D1010Tris pH 8.00.05 M GPEG 100010.0%(w/v)PPEG 20019.3%(v/v)
D1111Bicine pH 8.40.05 M HPEG 150010.0%(w/v)QPEG 30017.1%(v/v)
D1212Bicine pH 8.80.05 M IPEG 20008.6%(w/v)RPEG MME 35017.1%(v/v)
E11Acetate pH 4.80.05 M EPEG MME 5508.6%(v/v)UPEG 60022.9%(v/v)
E22Acetate pH 5.20.05 M FPEG 6008.6%(v/v)VPEG 100020.0%(w/v)
E33MES pH 5.60.05 M GPEG 10007.5%(w/v)WPEG 150020.0%(w/v)
E44MES pH 6.00.05 M HPEG 15007.5%(w/v)XPEG 200017.1%(w/v)
E55ADA pH 6.40.05 M IPEG 20006.4%(w/v)MPEG MME 200017.1%(w/v)
E66ADA pH 6.80.05 M JPEG MME 20006.4%(w/v)NPEG 300017.1%(w/v)
E77HEPES pH 7.10.05 M KPEG 30006.4%(w/v)OPEG 400014.3%(w/v)
E88HEPES pH 7.30.05 M LPEG 40006.4%(w/v)PPEG 20025.7%(v/v)
E99Tris pH 7.60.05 M APEG 2009.6%(v/v)QPEG 30022.9%(v/v)
E1010Tris pH 8.00.05 M BPEG 3008.6%(v/v)RPEG MME 35022.9%(v/v)
E1111Bicine pH 8.40.05 M CPEG MME 3508.6%(v/v)SPEG 40022.9%(v/v)
E1212Bicine pH 8.80.05 M DPEG 4008.6%(v/v)TPEG MME 55022.9%(v/v)
F11Acetate pH 4.80.05 M LPEG 40004.3%(w/v)WPEG 150025.0%(w/v)
F22Acetate pH 5.20.05 M APEG 2006.4%(v/v)XPEG 200021.4%(w/v)
F33MES pH 5.60.05 M BPEG 3005.7%(v/v)MPEG MME 200021.4%(w/v)
F44MES pH 6.00.05 M CPEG MME 3505.7%(v/v)NPEG 300021.4%(w/v)
F55ADA pH 6.40.05 M DPEG 4005.7%(v/v)OPEG 400017.9%(w/v)
F66ADA pH 6.80.05 M EPEG MME 5505.7%(v/v)PPEG 20032.1%(v/v)
F77HEPES pH 7.10.05 M FPEG 6005.7%(v/v)QPEG 30028.6%(v/v)
F88HEPES pH 7.30.05 M GPEG 10005.0%(w/v)RPEG MME 35028.6%(v/v)
F99Tris pH 7.60.05 M HPEG 15005.0%(w/v)SPEG 40028.6%(v/v)
F1010Tris pH 8.00.05 M IPEG 20004.3%(w/v)TPEG MME 55028.6%(v/v)
F1111Bicine pH 8.40.05 M JPEG MME 20004.3%(w/v)UPEG 60028.6%(v/v)
F1212Bicine pH 8.80.05 M KPEG 30004.3%(w/v)VPEG 100025.0%(w/v)
G11Acetate pH 4.80.05 M GPEG 10002.5%(w/v)MPEG MME 200025.7%(w/v)
G22Acetate pH 5.20.05 M HPEG 15002.5%(w/v)NPEG 300025.7%(w/v)
G33MES pH 5.60.05 M IPEG 20002.1%(w/v)OPEG 400021.4%(w/v)
G44MES pH 6.00.05 M JPEG MME 20002.1%(w/v)PPEG 20038.6%(v/v)
G55ADA pH 6.40.05 M KPEG 30002.1%(w/v)QPEG 30034.3%(v/v)
G66ADA pH 6.80.05 M LPEG 40002.1%(w/v)RPEG MME 35034.3%(v/v)
G77HEPES pH 7.10.05 M APEG 2003.2%(v/v)SPEG 40034.3%(v/v)
G88HEPES pH 7.30.05 M BPEG 3002.9%(v/v)TPEG MME 55034.3%(v/v)
G99Tris pH 7.60.05 M CPEG MME 3502.9%(v/v)UPEG 60034.3%(v/v)
G1010Tris pH 8.00.05 M DPEG 4002.9%(v/v)VPEG 100030.0%(w/v)
G1111Bicine pH 8.40.05 M EPEG MME 5502.9%(v/v)WPEG 150030.0%(w/v)
G1212Bicine pH 8.80.05 M FPEG 6002.9%(v/v)XPEG 200025.7%(w/v)
H11Acetate pH 4.80.05 M B   OPEG 400025.0%(w/v)
H22Acetate pH 5.20.05 M C   PPEG 20045.0%(v/v)
H33MES pH 5.60.05 M D   QPEG 30040.0%(v/v)
H44MES pH 6.00.05 M E   RPEG MME 35040.0%(v/v)
H55ADA pH 6.40.05 M F   SPEG 40040.0%(v/v)
H66ADA pH 6.80.05 M G   TPEG MME 55040.0%(v/v)
H77HEPES pH 7.10.05 M H   UPEG 60040.0%(v/v)
H88HEPES pH 7.30.05 M I   VPEG 100035.0%(w/v)
H99Tris pH 7.60.05 M J   WPEG 150035.0%(w/v)
H1010Tris pH 8.00.05 M K   XPEG 200030.0%(w/v)
H1111Bicine pH 8.40.05 M L   MPEG MME 200030.0%(w/v)
H1212Bicine pH 8.80.05 M A   NPEG 300030.0%(w/v)

Results

There were 116 crystallization hits overall for the experiments with the Pi minimal screen (Table 2 ▶). Some conditions produced hits for several samples (Table 3 ▶). The Pi-PEG screen yielded crystals that diffracted to 3.0 Å resolution for A2AR-GL31 with bound agonist. Fig. 3 ▶ shows the crystals of A2AR-GL31 obtained in well E9 [50 mM TrisHCl pH 7.6, 9.6%(v/v) PEG 200, 22.9%(v/v) PEG 300] and an example of the corresponding diffraction pattern (no cryoprotectant was required).
Figure 3

Crystals of A2AR-GL31 obtained with the Pi-PEG screen (Table 4 ▶) and an example of a corresponding diffraction pattern.

Discussion

In order to understand the rationale behind the modular arithmetic employed for the Pi sampling, it may help to imagine, on a 12 h clock, a series of events occurring every 5 h. The first event is at noon, the second at 5 pm, then 10 pm, then 3 am etc. Eventually, there is a succession of 12 events occurring at different hours, with as much time as possible in between each event. If we now look at combinations of three components, there are originally 123 or 1728 possibilities. Pi Sampler generates 96 of these combinations that correspond to conditions that are distant in properties. The variety between conditions is then accentuated using a number of different concentrations of solutions (Fig. 2 ▶). If the first and second sets of solutions are ordered according to physico-chemical properties, the generated screen will be an incomplete factorial sampling of interactions between chemicals with these properties. If the chemicals selected have completely different natures, they can be arranged randomly (see §2.3). The ordering of the third set of solutions can be used to avoid obvious chemical incompatibilities (e.g. mixing phosphate and magnesium salts). It is also possible to design simpler screens with only two sets of stock solutions.

The Pi minimal screen

In order to check the homogeneity of the hits across the screen with the ten samples, we compared the results obtained with what would be expected if each condition had the same probability of hits overall (Table 3 ▶). This can be approximated by a binomial distribution. The probability of success for the binomial distribution is the observed probability for ten attempts: 116/(10 × 96) = 0.12083. The χ2 statistic for the data is 3.48. This can be compared with the quantiles of a χ2 distribution with two degrees of freedom, which gives a p value of 0.18 (calculations not shown). This χ2 test indicates that no conditions are obvious outliers with regard to success or failure. There are, however, a multitude of possible biases implied when proceeding with crystallization experiments (which would be even more accentuated with the use of novel samples); hence, any statistical analysis should be taken with precaution. Nonetheless, it is interesting to see that the analysis of the distribution is in accordance with the original approach based on balanced randomization (Carter & Carter, 1979 ▶; Rupp, 2003 ▶). In addition, the conditions of the Pi minimal screen show no identities to the extensive list of conditions (7230) from commercial screens stored in the ‘PICKScreens’ database (Hedderich et al., 2011 ▶).

The Pi-PEG screen

The extent of effects on crystallization for precipitants such as PEGs is correlated with their concentrations (McPherson, 1976 ▶) and molecular weights (Forsythe et al., 2002 ▶). The Pi-PEG screen covers a wide range of parameters (kinetics of equilibrium, protein stabilization etc.). In addition, the con­centrations of the two different PEGs in a condition can be adjusted for condition optimization (Stock et al., 2005 ▶) and for crystal cryoprotection (Berejnov et al., 2006 ▶). Furthermore, the PICKScreens database shows that the Pi-PEG screen is unique (as for the Pi minimal screen; see §4.2). Samples of A2AR-GL31 purified in a number of different detergents rarely crystallized in commercially available screens used at the LMB (Stock et al., 2005 ▶) and when they did the crystal quality was not sufficient for structure determination. The first quality crystals were recently obtained using the Pi-PEG screen.

Conclusions

We have demonstrated that the Pi sampling is a methodical and flexible approach to initial screening for macromolecular crystallization. Two unique screens produced de novo have resulted from this strategy. The Pi minimal screen potentially has an ideal formulation for crystallization of novel soluble protein samples. The Pi-PEG screen is a tailor-made screen for GPCRs and potentially other membrane proteins generated by biasing the formulation towards components known to be essential. Further screens can be formulated with the Pi Sampler on a day-to-day basis in order to test chemicals and techniques, with the aim of increasing the yield of quality crystals. Also, new crystallization techniques are constantly emerging for macromolecular targets such as membrane proteins and hence formulations with special considerations are required: one may want to formulate screens compatible with the lipidic cubic phase (LCP) concept (Landau & Rosenbusch, 1996 ▶) or make extensive use of detergents (Koszelak-Rosenblum et al., 2009 ▶). In order for laboratories to be able to handle many Pi screen formulations and the flow of resulting data, we are working on the integration of Pi Sampler into the ‘xtalPiMS’ Laboratory Information Management System (LIMS; Morris et al., 2011 ▶; see http://www.pims-lims.org).
  17 in total

1.  Three-dimensional crystallization of the Escherichia coli glycerol-3-phosphate transporter: a member of the major facilitator superfamily.

Authors:  M Joanne Lemieux; Jinmei Song; Myong Jin Kim; Yafei Huang; Anthony Villa; Manfred Auer; Xiao-Dan Li; Da-Neng Wang
Journal:  Protein Sci       Date:  2003-12       Impact factor: 6.725

2.  Data mining crystallization databases: knowledge-based approaches to optimize protein crystal screens.

Authors:  Matthew S Kimber; François Vallee; Simon Houston; Alexander Necakov; Tatiana Skarina; Elena Evdokimova; Steven Beasley; Dinesh Christendat; Alexei Savchenko; Cheryl H Arrowsmith; Masoud Vedadi; Mark Gerstein; Aled M Edwards
Journal:  Proteins       Date:  2003-06-01

3.  Protein isoelectric point as a predictor for increased crystallization screening efficiency.

Authors:  Katherine A Kantardjieff; Bernhard Rupp
Journal:  Bioinformatics       Date:  2004-02-10       Impact factor: 6.937

Review 4.  Current approaches to macromolecular crystallization.

Authors:  A McPherson
Journal:  Eur J Biochem       Date:  1990-04-20

5.  Lipidic cubic phases: a novel concept for the crystallization of membrane proteins.

Authors:  E M Landau; J P Rosenbusch
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

6.  Crystallization of ribozymes and small RNA motifs by a sparse matrix approach.

Authors:  J A Doudna; C Grosshans; A Gooding; C E Kundrot
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

7.  Protein crystallization using incomplete factorial experiments.

Authors:  C W Carter; C W Carter
Journal:  J Biol Chem       Date:  1979-12-10       Impact factor: 5.157

8.  Crystallization of proteins from polyethylene glycol.

Authors:  A McPherson
Journal:  J Biol Chem       Date:  1976-10-25       Impact factor: 5.157

9.  Vapor diffusion, nucleation rates and the reservoir to crystallization volume ratio.

Authors:  Elizabeth L Forsythe; Daniel L Maxwell; Marc Pusey
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2002-09-26

10.  The Protein Information Management System (PiMS): a generic tool for any structural biology research laboratory.

Authors:  Chris Morris; Anne Pajon; Susanne L Griffiths; Ed Daniel; Marc Savitsky; Bill Lin; Jonathan M Diprose; Alan Wilter da Silva; Katya Pilicheva; Peter Troshin; Johannes van Niekerk; Neil Isaacs; James Naismith; Colin Nave; Richard Blake; Keith S Wilson; David I Stuart; Kim Henrick; Robert M Esnouf
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18
View more
  13 in total

1.  A Disulfide Bond-forming Machine Is Linked to the Sortase-mediated Pilus Assembly Pathway in the Gram-positive Bacterium Actinomyces oris.

Authors:  Melissa E Reardon-Robinson; Jerzy Osipiuk; Chungyu Chang; Chenggang Wu; Neda Jooya; Andrzej Joachimiak; Asis Das; Hung Ton-That
Journal:  J Biol Chem       Date:  2015-07-13       Impact factor: 5.157

2.  Crystal structure of Bacillus anthracis virulence regulator AtxA and effects of phosphorylated histidines on multimerization and activity.

Authors:  Troy G Hammerstrom; Lori B Horton; Michelle C Swick; Andrzej Joachimiak; Jerzy Osipiuk; Theresa M Koehler
Journal:  Mol Microbiol       Date:  2014-12-30       Impact factor: 3.501

3.  A thiol-disulfide oxidoreductase of the Gram-positive pathogen Corynebacterium diphtheriae is essential for viability, pilus assembly, toxin production and virulence.

Authors:  Melissa E Reardon-Robinson; Jerzy Osipiuk; Neda Jooya; Chungyu Chang; Andrzej Joachimiak; Asis Das; Hung Ton-That
Journal:  Mol Microbiol       Date:  2015-09-25       Impact factor: 3.501

4.  Porous nucleating agents for protein crystallization.

Authors:  Sahir Khurshid; Emmanuel Saridakis; Lata Govada; Naomi E Chayen
Journal:  Nat Protoc       Date:  2014-06-12       Impact factor: 13.491

5.  Structural Basis of a Thiol-Disulfide Oxidoreductase in the Hedgehog-Forming Actinobacterium Corynebacterium matruchotii.

Authors:  Truc Thanh Luong; Reyhaneh Tirgar; Melissa E Reardon-Robinson; Andrzej Joachimiak; Jerzy Osipiuk; Hung Ton-That
Journal:  J Bacteriol       Date:  2018-04-09       Impact factor: 3.490

6.  Sparse and incomplete factorial matrices to screen membrane protein 2D crystallization.

Authors:  R Lasala; N Coudray; A Abdine; Z Zhang; M Lopez-Redondo; R Kirshenbaum; J Alexopoulos; Z Zolnai; D L Stokes; I Ubarretxena-Belandia
Journal:  J Struct Biol       Date:  2014-12-03       Impact factor: 2.867

7.  Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation.

Authors:  Guillaume Lebon; Tony Warne; Patricia C Edwards; Kirstie Bennett; Christopher J Langmead; Andrew G W Leslie; Christopher G Tate
Journal:  Nature       Date:  2011-05-18       Impact factor: 49.962

8.  Structural and Functional Analysis of Human HtrA3 Protease and Its Subdomains.

Authors:  Przemyslaw Glaza; Jerzy Osipiuk; Tomasz Wenta; Dorota Zurawa-Janicka; Miroslaw Jarzab; Adam Lesner; Bogdan Banecki; Joanna Skorko-Glonek; Andrzej Joachimiak; Barbara Lipinska
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

9.  The current approach to initial crystallization screening of proteins is under-sampled.

Authors:  Fabrice Gorrec
Journal:  J Appl Crystallogr       Date:  2013-04-18       Impact factor: 3.304

Review 10.  Protein crystallization screens developed at the MRC Laboratory of Molecular Biology.

Authors:  Fabrice Gorrec
Journal:  Drug Discov Today       Date:  2016-03-24       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.